-
公开(公告)号:US06441038B1
公开(公告)日:2002-08-27
申请号:US09686629
申请日:2000-10-12
Applicant: Cari Loder , David F. Horrobin
Inventor: Cari Loder , David F. Horrobin
IPC: A61K31195
CPC classification number: A61K31/55 , A61K45/06 , A61K2300/00
Abstract: A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack.# The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.
Abstract translation: 公开了一种治疗神经源性疾病的方法和用于该方法的药物制剂。 这些病症包括与慢性疲劳综合征,脑损伤和中风,压力,纤维肌痛和肠易激综合征相关的疲劳和相关的疼痛,虚弱和抑郁情绪综合征。 该治疗包括向有需要的患者施用去甲肾上腺素再摄取的选择性抑制剂与相同剂型或相同包装中的苯丙氨酸或酪氨酸组合。#去甲肾上腺素能药可以选自洛哌匹灵,地昔帕明或瑞波西汀。 选择性抑制剂可以是去甲肾上腺素和5-羟色胺再摄取的组合抑制剂,如文拉法辛,度洛西汀或米那普仑,或去甲肾上腺素和多巴胺再摄入如安非他酮的抑制剂。
-
公开(公告)号:US5888541A
公开(公告)日:1999-03-30
申请号:US784105
申请日:1997-01-15
Applicant: David F. Horrobin , Brenda E. Reynolds
Inventor: David F. Horrobin , Brenda E. Reynolds
IPC: A61K31/201 , A61K35/78 , A61K9/20
CPC classification number: A61K31/201
Abstract: Increase gut calcium absorption in humans or animals by the administration of GLA, DGLA or LA as such or in salt or other pharmacologically acceptable form, optionally in association with EPA, DHA or other EFA in similar forms, specifically useful in the treatment of osteoporosis.
Abstract translation: 通过施用GLA,DGLA或LA本身或以盐或其他药理学上可接受的形式,任选地与EPA,DHA或其他类似形式的EFA相关联地增加对人或动物的肠吸收钙吸收,特别可用于治疗骨质疏松症。
-
公开(公告)号:US5871757A
公开(公告)日:1999-02-16
申请号:US628692
申请日:1996-10-16
Applicant: John B. Cloughley , David F Horrobin
Inventor: John B. Cloughley , David F Horrobin
CPC classification number: C11B5/0085 , A23D9/06
Abstract: Polyunsaturated oils such as triply or higher ethylenically unsaturated organic materials are stabilized against ambient temperature atmospheric oxidation by the addition of an essential oil such as thyme oil, oregano oil, pepper oil or clove oil.
Abstract translation: PCT No.PCT / GB94 / 02277 Sec。 371日期1996年10月16日第 102(e)日期1996年10月16日PCT 1994年10月18日PCT公布。 WO95 / 11289 PCT出版物 日期1995年04月27日多不饱和油如三元或更高的烯键式不饱和有机材料通过加入精油如百里香油,牛至油,胡椒油或丁香油,稳定于环境温度大气氧化。
-
公开(公告)号:US5866703A
公开(公告)日:1999-02-02
申请号:US543799
申请日:1995-10-16
Applicant: David F. Horrobin , Austin McMordie , Mehar Singh Manku , Philip Knowles
Inventor: David F. Horrobin , Austin McMordie , Mehar Singh Manku , Philip Knowles
IPC: A23D9/00 , A23L1/30 , A61K8/11 , A61K8/30 , A61K8/37 , A61K31/23 , A61K31/232 , A61P17/00 , A61P25/28 , A61P29/00 , A61P37/08 , C07C69/52 , C07C69/587 , C11C3/00 , C07C57/00
CPC classification number: A61K31/232 , A23L33/12 , A61K31/23 , C07C69/52 , C07C69/587
Abstract: Triglycerides with at least two different acids chosen from 6-desaturated essential fatty acids and oleic acid, useful in nutrition and in medicine.
Abstract translation: 具有至少两种选自6-去饱和必需脂肪酸和油酸的不同酸的甘油三酸酯,可用于营养和医学。
-
公开(公告)号:US5620701A
公开(公告)日:1997-04-15
申请号:US600005
申请日:1996-02-14
Applicant: David F. Horrobin , Yung-Sheng Huang
Inventor: David F. Horrobin , Yung-Sheng Huang
IPC: A61K31/23 , A23D9/00 , A23L1/30 , A61K8/00 , A61K8/30 , A61K8/37 , A61K8/96 , A61P13/02 , A61P15/00 , A61P17/00 , A61P25/04 , A61Q5/00 , A61Q19/00 , C07C69/587 , C11B3/10 , C11B7/00 , C11D3/06 , A61K9/70 , A61K9/14 , A61K31/20 , A61K47/12
CPC classification number: A23D9/00 , A61K31/23 , C07C69/587
Abstract: Atopic eczema, breast pain or premenstrual syndrome are treated by administering to a person in need of same a composition containing at least 20% di-linoleoyl-mono-gamma-linolenyl glycerol by weight.
-
公开(公告)号:US5583159A
公开(公告)日:1996-12-10
申请号:US408135
申请日:1995-03-21
Applicant: David F. Horrobin , Catherine A. Scott
Inventor: David F. Horrobin , Catherine A. Scott
IPC: A61K31/20 , A61K31/202 , A61P25/00 , A61P43/00
CPC classification number: A61K31/202 , A61K31/20
Abstract: Damage to internal tissues, and particularly to the central nervous system as a consequence of exposure to ionizing radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.
Abstract translation: 通过施用GLA和/或DGLA来防止或治疗由于暴露于电离辐射而对内部组织,特别是对中枢神经系统的损伤。 含有GLA和/或DGLA用于治疗或预防的药物还可以进一步包含EPA和/或DHA。
-
公开(公告)号:US5508307A
公开(公告)日:1996-04-16
申请号:US378708
申请日:1995-01-26
Applicant: David F. Horrobin , Catherine A. Scott
Inventor: David F. Horrobin , Catherine A. Scott
IPC: A61K31/20 , A61K20060101 , A61K9/08 , A61K31/201 , A61K31/202 , A61K31/203 , A61K33/00
CPC classification number: A61K31/20
Abstract: Method of safe intravenous administration of fatty acid(s), and in particular the n-6 and n-3 series essential fatty acids and conjugated fatty acids, whereby the fatty acid(s) or a proportion thereof are administered in the form of lithium salts, and whereby the plasma lithium levels are regularly monitored to avoid haemolysis, preferably keeping the lithium level no higher than 0.7 millimolar in the long term and preferably also no higher than 0.4-0.5 millimolar in the first 24-48 hours or, where only a proportion of the fatty acids are administered as lithium salts, a corresponding proportion of said levels.
Abstract translation: 脂肪酸的安全静脉内给药方法,特别是n-6和n-3系列必需脂肪酸和共轭脂肪酸,其中脂肪酸或其一部分以锂的形式施用 盐,并且由此定期监测血浆锂水平以避免溶血,优选在长期内保持锂水平不高于0.7毫摩尔,优选在第一24-48小时内不超过0.4-0.5毫摩尔,或者仅在 一部分脂肪酸以锂盐的形式施用,相应比例的水平。
-
公开(公告)号:US5264217A
公开(公告)日:1993-11-23
申请号:US959472
申请日:1992-10-09
Applicant: David F. Horrobin
Inventor: David F. Horrobin
IPC: A61K31/20
CPC classification number: A61K31/20 , Y10S514/922
Abstract: Methods for increasing the total fat and therefore energy content of mammalian and particularly human milk, the essential fatty acid content of that milk and the flow of that milk during lactation, or for preventing or reducing the normal decrease in milk fat content that occurs during prolonged lactation, by administering gamma linolenic acid, dihomo-gamma-linolenic acid or their mixture, alone or a physiologically acceptable diluent or carrier, in a form administrable to the lactating female.
Abstract translation: 增加哺乳动物和特别是人乳的总脂肪,因此能量含量的方法,该乳的必需脂肪酸含量和哺乳期间该奶的流动,或用于预防或减少在长时间内发生的乳脂含量的正常降低 通过以可施用于哺乳期雌性的形式单独或单独或生理上可接受的稀释剂或载体施用γ-亚麻酸,二亚非 - γ-亚麻酸或其混合物。
-
公开(公告)号:US5262174A
公开(公告)日:1993-11-16
申请号:US732492
申请日:1991-07-18
Applicant: David F. Horrobin
Inventor: David F. Horrobin
IPC: A61K31/19 , A61K31/505 , A61K33/14 , A61K38/21 , A61K31/70
CPC classification number: A61K31/70 , A61K31/19 , A61K31/505 , A61K33/14 , A61K38/21
Abstract: The treatment of viral infections with a lithium salt and one of cytarabine or idoxuridine.
Abstract translation: 用盐酸盐治疗病毒感染,阿糖尿病或阿托脲治疗。
-
公开(公告)号:US5252333A
公开(公告)日:1993-10-12
申请号:US329881
申请日:1989-03-28
Applicant: David F. Horrobin
Inventor: David F. Horrobin
IPC: A01N37/06 , A23L1/304 , A61K8/19 , A61K8/36 , A61K8/67 , A61K9/28 , A61K31/20 , A61L15/44 , A61Q5/02 , A61Q19/00 , A61F13/00 , A61K9/00
CPC classification number: A61K8/67 , A01N37/06 , A23L33/16 , A61K31/20 , A61K8/19 , A61K8/361 , A61Q19/00 , A61Q5/02 , Y10S514/81 , Y10S514/821 , Y10S514/824 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/886 , Y10S514/905 , Y10S514/931 , Y10S514/934 , Y10S514/943
Abstract: The invention provides pharmaceutical and disinfectant compositions containing lithium salts of C.sub.18-22 polyunsaturated fatty acids. The compositions may be used in the treatment of conditions responsive to lithium and/or polyunsaturated fatty acid therapy, in parenteral alimentation or food supplements or in surface disinfection to combat transmission of viral diseases.
Abstract translation: 本发明提供含有C18-22多不饱和脂肪酸的锂盐的药物和消毒剂组合物。 组合物可用于治疗对锂和/或多不饱和脂肪酸治疗,肠胃外营养或食物补充剂或表面消毒作用以对抗病毒性疾病传播的病症。
-
-
-
-
-
-
-
-
-